Clinical Trial Update: A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating acoramidis modified-release formulations in healthy subjects has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• Acoramidis (acoramidis)

Snippet

Sponsor: Eidos Therapeutics, a BridgeBio company | Conditions: Amyloidosis | Phase 1 | Status: COMPLETED